Sales Growth YoY (Last 12 Months): preludetx.com (PRLD)

Prelude Therapeutics (PRLD) is developing scientific partnerships with oncology centers to create tumor-suppressing drugs, which is supported by the rolling annual revenue growth rate, where the value of 105.70 expresses the metric level. Capital-intensive inhibitor trials create negative operating leverage in the absence of revenue. High barriers to entry are driven by strict FDA oversight and the cost of patents for targeted therapy.
Summary analytical data breakdowns for preludetx.com (PRLD)

This indicator captures the objective balance of supply and demand, reflecting real annual revenue growth. The calculation is based on a comparison of the current twelve months with the same period last year to eliminate seasonality. By analyzing the annual revenue growth rate over a rolling four quarters, an investor assesses the operational resilience of the asset. For Prelude Therapeutics (PRLD), the metric's trend reflects the specifics of early clinical expansion for targeted inhibitors. The absence of large-scale sales confirms the molecule development stage and the focus on protecting intellectual property rights.